

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage
- Roy Herbst named director at Dartmouth Cancer Center
- In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt










